Oncotype DX Test for Breast Cancer
One Factor in Many
The results of your tests alone aren’t enough to determine your treatment. Your doctor will also consider the tumor size and grade, the number of hormone receptors in your cancer, and your age before recommending a treatment plan.
A large study called the TAILORx trial is under way with women who have a mid-range score. Researchers want more precise information on which types of breast cancer need chemo to stop them from coming back, and which cancers don't.
Other Gene Tests
Other genome tests show promise in helping treat early-stage breast cancer, but more research is needed.
MammaPrint looks at 70 different genes within the cells of a breast tumor and helps predict whether cancer is likely to spread beyond the breast. This test can be used for tumors that are ER+ or ER-.
The Mammostrat test measures five genes to determine the risk for early-stage hormone receptor-positive disease coming back.
The Prosigna assay looks at early-stage hormone receptor-positive disease in postmenopausal women (with up to three positive lymph nodes). It analyzes 58 genes and calculates the risk of cancer coming back somewhere else in the body within 10 years of diagnosis after hormone therapy.